logo
  

Svenska Handelsbanken Q2 Profit Surges

Svenska Handelsbanken AB (SVNLF.PK,SVNLY.PK), a Swedish lender, on Wednesday reported a surge in profit for the second-quarter, particularly on higher net interest income.

For the second-quarter to June, the Stockholm-headquartered company posted a profit of SEK 7.104 billion or SEK 3.59 per share, compared with SEK 4.212 billion or SEK 2.13 per share of previous year quarter.

Operating earnings were at SEK 8.841 billion as against SEK 5.281 billion a year ago.

Profit for the period from discontinued operations after tax surged to SEK 329 million from SEK 73 million of 2022.

Profit before credit losses, risk tax and resolution fee was at SEK 9.531 billion, versus previous year's SEK 5.927 billion. Total income moved up to SEK 15.166 billion from SEK 11.053 billion of 2022.

Net interest income stood at SEK 11.687 billion, versus SEK 8.390 billion a year ago.

Net fee and commission income rose to SEK 2.761 billion from SEK 2.710 billion of prior year quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Microsoft has launched a new category of Windows PCs designed for Artificial Intelligence (AI) that are slated to be the fastest and most intelligent Windows PCs ever built. The Copilot+ PCs come with built-in AI hardware and will support AI features across the operating system. Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit. While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings...

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
RELATED NEWS
Follow RTT